A new Johns Hopkins pilot study found that a single dose of psilocybin, combined with cognitive behavioral therapy, helped 40.5% of smokers stay quit at six months. The nicotine patch group: 10%. The study involved eighty-two participants, randomly assigned, and all biochemically verified as having actually quit. If the numbers hold up in larger trials, psilocybin would be the most effective smoking cessation tool ever studied. Smoking kills 480,000 Americans a year. The best existing medication — varenicline — gets about 25-35%. The study came out yesterday, along with a number of caveats.
1. This Could Be Huge (Johns Hopkins Researchers, Psychedelic Therapy Advocates)
A single dose outperformed the nicotine patch by a factor of four. Nothing else comes close.
The mechanism is completely different from anything in the quit-smoking toolkit. Psilocybin doesn't target nicotine receptors. It doesn't replace the drug or mimic it. Outside specialists told NPR it likely triggers a "perspective shift" that strengthens the impact of therapy. The combination matters: psilocybin plus a 13-week CBT program, not psilocybin alone.
The results are biochemically verified, not self-reported. Both groups got the same therapy. Only the intervention differed. At six months, 17 of 42 psilocybin participants had verifiably quit, versus 4 of 40 on the patch. A larger trial funded by the National Institute on Drug Abuse is already underway, with a placebo arm and brain-imaging analyses planned.
Oregon and Colorado are already running legal psilocybin programs. Oregon launched the nation's first regulated program in 2023 with over 10,000 participants and a 99.6% incident-free rate. Colorado opened licensed services in June 2025. The infrastructure for therapeutic psilocybin exists. Now evidence is catching up, including this study.
2. Slow Down (Clinical Trial Skeptics, Statisticians)
Eighty-two people. Open-label. Eighty-nine percent White. This is a pilot, not a verdict.
The study has real limitations and the authors know it. The sample was 82 people. About 89% of participants were White. And it was open-label — both participants and investigators knew who got psilocybin and who got the patch. That's a problem. Open-label designs can inflate effect sizes because expectation alone changes behavior, especially with a substance as culturally loaded as psilocybin.
The safety profile isn't clean. Headaches and brief blood-pressure elevations were more common in the psilocybin arm. The authors themselves call the findings "preliminary." Blinding is inherently difficult with psychedelics — the experience is the intervention, and you can't fake it with a sugar pill — which makes designing a rigorous trial genuinely hard.
3. The FDA Won't Touch This (Trump Administration, Drug Policy Skeptics)
The science can say whatever it wants. The politics say no.
The Trump administration already blocked a psilocybin fast-track. STAT News reported in February that administration officials vetoed the FDA's plan to fast-track psilocybin review for severe depression. And during the Biden Admin, the FDA advisory committee voted overwhelmingly against MDMA-assisted therapy. The regulatory path for psychedelics is narrowing, not widening, at the federal level.
States are moving faster than the FDA, and that worries people. Harvard's Petrie-Flom Center wrote that "States, Not the FDA, Are Winning the Drug War." Oregon and Colorado have legalized therapeutic psilocybin, but skeptics point to real problems: no mechanism for verifying chemical content outside medical settings, and a lack of training and licensure standards for providers.
The support base is still small. Only 25% of US adults support legal psilocybin use, and just about 10% support MDMA or LSD legalization. Phase 3 trial results for several psychedelic medications are expected in late 2026 or early 2027. This smoking trial could shift the conversation — or it could get lost in the political noise around psychedelics more broadly.
Where This Lands
Forty percent quit rates from a single dose is extraordinary if it holds. But this is 82 people, open-label, and the federal government is openly skeptical about psychedelics for treatment. The science (along with individual states) may be ahead of the politics, which seems to be entrenched. The larger trial with a placebo arm will matter more than this one. Until then, we have a very promising pilot and a federal government that doesn't want to hear about it.